Kar Wong

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

Jean‐Louis Vincent, Gordon R. Bernard, Richard Beale et al. · Critical Care Medicine · 2005 · 320 citations

Extended Evaluation of Recombinant Human Activated Protein C United States Trial (ENHANCE US)

Gordon R. Bernard, Benjamin D. Margolis, Harvey M. Shanies et al. · CHEST Journal · 2004 · 162 citations

Translational Medicine, Extended Evaluation, Enhance Us +5

Ammonia clearance by peritoneal dialysis and continuous arteriovenous hemodiafiltration

Kar Wong, Sik Nin Wong, Shu Yan Lam et al. · Pediatric Nephrology · 1998 · 64 citations · Full text

Hemodialysis, Ammonia Clearance, Dialysis +5

End-of-life Characteristics and Palliative Care Provision for Patients With Motor Neuron Disease

Hon Wai Benjamin Cheng, Oi Man Iman Chan, Chun Hung Chan et al. · American Journal of Hospice and Palliative Medicine® · 2017 · 24 citations

Motor Dysfunction, Motor Neuron Disease, Neurological Disorder +28

Baseline Characteristics and Survival of Adult Severe Sepsis Patients Treated With Drotrecogin Alfa (Activated) in a Global, Single-Arm, Open-Label Trial (ENHANCE

Arthur P. Wheeler, Christopher Doig, Theressa J. Wright et al. · CHEST Journal · 2003 · 14 citations · Full text

Open-label Trial, Acute Care, Clinical Trials +8